Raison et al. [18] could prove in a cross-sectional assessment 12 weeks after the start of IFN-α therapy that patients with chronic HCV-infection had a higher concentration of quinolinic acid in their cerebrospinal fluid in comparison with untreated controls. The gene discussed is IFNA17; the disease is infection.